Work

Long-lasting recombinant HEXA treatment improves hepatic steatosis and glycemic control in mild, but not severe, metabolic dysfunction-associated steatohepatitis

Year: 2025

Type: article

Abstract: The prevalence of metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes is increasing. Here, we show that chronic FC-HEXA recombinant protein treatment reduces hepatic lipid accumulation and improves blood glucose control in mice with mild MASH and insulin resistance.

Source: American Journal of Physiology-Endocrinology and Metabolism

DOI: 10.1152/ajpendo.00359.2024

Authors: Sihan Lin, Li Dong, William De Nardo, Michael G. Leeming, Zhili Cheng, Nicholas A. Williamson, Matthew J. Watt, Magdalene K. Montgomery

Institution: The University of Melbourne

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: Department of Health and Aged Care, Australian Government, National Health and Medical Research Council

Awards: Deciphering the metabolic and endocrine profile of healthy adipocytes, Development of multifaceted glucose-plus therapies - A focus on Hexosaminidase A (HEXA), G6483474468, Discovery and validation of biomarkers for nonalcoholic steatohepatitis and liver fibrosis, G7994138630, G976871043

OpenAlex ID: W4407342207

FWCI: 0.607

Cites: 69

Cited by: 1

Related to: 10